- Quest Diagnostics and Broad Clinical Labs to Evaluate Whole Genome Sequencing as First-Line Genetic Test for Developmental Delay
- Study in Frontiers in Neurology Affirms Amyloid Blood Test Can Help Identify Patients Who May Forgo Imaging Evaluation for Alzheimer's Disease
- Quest Diagnostics to Release First Quarter 2024 Financial Results on April 23, 2024
- Quest Diagnostics to Speak at the Barclays 26th Annual Global Healthcare Conference
- Quest Diagnostics and Instacart Collaborate to Reduce Food Insecurity Across the United States with Integrated Patient Health Coaching and Nutritious Grocery Delivery
- Freenome Raises $254 Million in New Funding to Accelerate its Platform for Early Cancer Detection
- Quest Diagnostics Debuts MelaNodal Predict™ Test, Personalizing Melanoma Risk Prediction to Help Patients Forgo Invasive Surgery
- First PFAS "Forever Chemicals" Consumer-Initiated Blood Test with Physician Consult Launches on questhealth.com
- Quest Diagnostics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Guidance for Full Year 2024; Increases Quarterly Dividend 5.6% to $0.75 Per Share
- Ten Years Running: FORTUNE Names Quest Diagnostics one of 2024 "World's Most Admired Companies"
More ▼
Key statistics
On Friday, Quest Diagnostics Inc (DGX:NYQ) closed at 128.19, 7.19% above its 52-week low of 119.59, set on Oct 02, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 126.52 |
---|---|
High | 128.88 |
Low | 126.08 |
Bid | 128.17 |
Offer | 128.20 |
Previous close | 125.91 |
Average volume | 756.49k |
---|---|
Shares outstanding | 111.06m |
Free float | 110.58m |
P/E (TTM) | 16.82 |
Market cap | 13.98bn USD |
EPS (TTM) | 7.49 USD |
Annual div (ADY) | 3.00 USD |
---|---|
Annual div yield (ADY) | 2.38% |
Div ex-date | Apr 05 2024 |
Div pay-date | Apr 22 2024 |
Data delayed at least 15 minutes, as of Apr 19 2024 20:48 BST.
More ▼